The Resurgence of U.S. Pharmaceutical Manufacturing
The pandemic exposed a hard truth about America’s dependence on foreign pharmaceutical production. Over the past two decades, the drive to move manufacturing offshore to reduce costs left the nation vulnerable when global supply chains were disrupted.
Recognizing this as both a health and national security risk, the U.S. government is now actively supporting the return of pharmaceutical and biotechnology manufacturing to domestic soil. This shift has sparked the announcement of numerous large-scale capital projects across the country.
